MX2021006941A - Anelosomas para suministrar modalidades terapéuticas intracelulares. - Google Patents

Anelosomas para suministrar modalidades terapéuticas intracelulares.

Info

Publication number
MX2021006941A
MX2021006941A MX2021006941A MX2021006941A MX2021006941A MX 2021006941 A MX2021006941 A MX 2021006941A MX 2021006941 A MX2021006941 A MX 2021006941A MX 2021006941 A MX2021006941 A MX 2021006941A MX 2021006941 A MX2021006941 A MX 2021006941A
Authority
MX
Mexico
Prior art keywords
anellosomes
therapeutic modalities
intracellular therapeutic
delivering intracellular
delivering
Prior art date
Application number
MX2021006941A
Other languages
English (en)
Spanish (es)
Inventor
Avak Kahvejian
Erica Gabrielle Weinstein
Simon Delagrave
Nathan Lawrence Yozwiak
Kevin James Lebo
Fernando Martin Diaz
Dhananjay Maniklal Nawandar
Ryan D Tedstone
Jared David Pitts
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MX2021006941A publication Critical patent/MX2021006941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021006941A 2018-12-12 2019-12-12 Anelosomas para suministrar modalidades terapéuticas intracelulares. MX2021006941A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778851P 2018-12-12 2018-12-12
US201862778866P 2018-12-12 2018-12-12
PCT/US2019/065874 WO2020123753A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities

Publications (1)

Publication Number Publication Date
MX2021006941A true MX2021006941A (es) 2021-11-17

Family

ID=69160334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006941A MX2021006941A (es) 2018-12-12 2019-12-12 Anelosomas para suministrar modalidades terapéuticas intracelulares.

Country Status (11)

Country Link
US (1) US20220040117A1 (enExample)
EP (1) EP3894567A2 (enExample)
JP (2) JP2022514501A (enExample)
KR (1) KR20210131308A (enExample)
CN (1) CN114127302A (enExample)
AU (1) AU2019396516B2 (enExample)
BR (1) BR112021009282A2 (enExample)
CA (1) CA3119339A1 (enExample)
IL (1) IL283771A (enExample)
MX (1) MX2021006941A (enExample)
WO (1) WO2020123753A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
AU2021288320A1 (en) * 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
US20240197823A1 (en) * 2021-02-12 2024-06-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cationic antimicrobial peptides and uses thereof
TW202334423A (zh) 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒
AU2023272105A1 (en) * 2022-05-19 2024-10-03 Flagship Pioneering Innovations V, Inc. Compositions comprising modified anellovirus capsid proteins and uses thereof
US20240415978A1 (en) * 2023-06-14 2024-12-19 Flagship Pioneering Innovations V, Inc. Anellovectors for delivery of effectors to the central nervous system
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof

Also Published As

Publication number Publication date
IL283771A (en) 2021-07-29
WO2020123753A2 (en) 2020-06-18
JP7898475B2 (ja) 2026-07-31
AU2019396516B2 (en) 2026-04-16
CA3119339A1 (en) 2020-06-18
JP2024102242A (ja) 2024-07-30
WO2020123753A3 (en) 2020-07-23
JP2022514501A (ja) 2022-02-14
US20220040117A1 (en) 2022-02-10
BR112021009282A2 (pt) 2021-08-17
CN114127302A (zh) 2022-03-01
KR20210131308A (ko) 2021-11-02
AU2019396516A1 (en) 2021-05-27
EP3894567A2 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
IL268999A (en) Compounds and preparations for intracellular administration of medicinal agents
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX2023010042A (es) Polinucleotidos moduladores.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022012374A (es) Composiciones multi-suplementos.
GEP20217239B (en) Pharmaceutical composition
PH12016501578A1 (en) Pharmaceutical compounds
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
GB2541571A (en) Pharmaceutical compositions
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
WO2020123773A3 (en) Anellosomes for delivering secreted therapeutic modalities
PH12016501702B1 (en) Pyrazole amide derivative
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2019005833A (es) Administracion transdermica de agentes grandes.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
GEP20217240B (en) Pharmaceutical composition
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12017502028A1 (en) Vortioxetine pyroglutamate
SG10201900598TA (en) Factor viii formulation
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.